Factor VIII anticorps

N° du produit ABIN111959

L’anticorps anti-Factor VIII Monoclonal Souris est utilisé pour la détection de Factor VIII dans des échantillons de Humain. Il a été validé pour EIA.

Aperçu rapide pour Factor VIII anticorps (ABIN111959)

Antigène: Factor VIII (F8) (Coagulation Factor VIII (F8))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp Factor VIII est non-conjugé

Application: Enzyme Immunoassay (EIA)

Clone: 2A5

Détail du produit anti-Factor VIII anticorps

Specificité: This antibody recognizes the 83 kDa light chain of Factor VIII. It does not cross-react with Von Willebrand factor.

Purification: Affinity Chromatography on Protein A

Immunogène: Purified Human Factor VIII

Isotype: IgG2a

Information d'application

Indications d'application: ELISA. Functional assays.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 1.0 mg/mL

Buffer: PBS, pH 7.2 containing 0.09 % Sodium Azide as preservative

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Détails sur Factor VIII

Antigène: Factor VIII (F8) (Coagulation Factor VIII (F8))

Sujet: Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa. It is an extracellular factor. Defects in F8 are the cause of hemophilia A (HEMA). HEMA is a common recessive X linked coagulation disorder. The frequency of hemophilia A is 1-2 in 10,000 male births in all ethnic groups. About 50 % of patients have severe hemophilia A with F8C activity less than 1 % of normal, they have frequent spontaneous bleeding into joints, muscles and internal organs. Moderately severe hemophilia A occurs in about 10 % of patients, F8C activity is 2-5 % of normal, and there is bleeding after minor trauma. Mild hemophilia A, which occurs in 30-40 % of patients, is associated with F8C activity of 5-30 % and bleeding occurs only after significant trauma or surgery. Of particular interest for the understanding of the function of F8C is the category of CRM (cross-reacting material) positive patients (approximately 5 %) that have considerable amount of F8C in their plasma (at least 30 % of normal), but the protein is nonfunctional, i.e., the F8C activity is much less than the plasma protein level. CRM reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.Synonyms: AHF, Antihemophilic factor, F8C, Procoagulant component

ID gène: 2157

NCBI Accession: NP_000123

UniProt: P00451